Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — Investor Presentation (December 2021)

21 slides from Satellos Bioscience's investor presentation, December 2021

  1. Slide 1: Restoring regeneration to treat dystrophies and ageing

    Slide 1: Restoring regeneration to treat dystrophies and ageing

    Restoring regeneration to treat Satellos Bioscience Inc. dystrophies and agein TSXV: MSCL Dec. 2021 Rebuilding muscle from within TM g

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements Certain statements in this presentation are “forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alw

  3. Slide 3: Disclaimers; No solicitation

    Slide 3: Disclaimers; No solicitation

    3 Disclaimers; No solicitation This presentation is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would

  4. Slide 4: Overview

    Slide 4: Overview

    4 Muscle is the largest organ in OVERVIEW the human body Muscle regenerates Satellos science Positioning for success ▪ Defining role of muscle stem ▪ World leading expertise Satellite Cell and cells in regeneration strong founding team ▪ Trailblazing discoveries that are ▪ Validation from preeminent

  5. Slide 5: Satellos scientific founder: World leader in muscle stem cell research

    Slide 5: Satellos scientific founder: World leader in muscle stem cell research

    5 Satellos scientific founder: World leader in muscle stem cell research Identification of Duchenne is a muscle muscle stem cells stem cell disease 2000 2009 2013 2016 Dr. Michael Rudnicki Continuous track record in elite scientific journals Ottawa Hosp. Res. Inst. 2007 2012 2015 2019 ❖ Order of Can

  6. Slide 6: Muscle (aka satellite) stem cells drive muscle regeneration

    Slide 6: Muscle (aka satellite) stem cells drive muscle regeneration

    6 Muscle (aka satellite) stem cells: Drive muscle regeneration Reside in a niche” deep Divide to create two types within muscle of muscle cells Niche Stem cell Muscle stem cells Muscle progenitor cells (self-renewal) (differentiation) Ongoing regeneration requires both cell types in balance 6

  7. Slide 7: MyoReGenX: Proprietary discovery platform for muscle regeneration

    Slide 7: MyoReGenX: Proprietary discovery platform for muscle regeneration

    7 MyoReGenX™: Proprietary discovery platform for muscle regeneration Phenotypic Regeneration Assay Drug Screening Cascade Candidates IN Enzyme Activity SPR Binding Gate In-vitro ➢ 1 Human Myoblast Activity Gate Cellular ➢ 2 Stem Cell Balance Gate 3 ➢ Ex-vivo Leads OUT Designed for target discovery a

  8. Slide 8: Regenerative failure caused by impairments to stem cell divisions

    Slide 8: Regenerative failure caused by impairments to stem cell divisions

    8 Regenerative failure Caused by impairments to stem cell divisions Ageing Duchenne Satellite Cell Impairment Stem Impairment cell X X Balance Not enough stem cells Not enough progenitors ➢ Sarcopenia ➢ Cachexia ➢ Sports Injury ➢ SMA ➢ Trauma/surgery ➢ Other dystrophies Healthy Regeneration :

  9. Slide 9: Our solution in Duchenne: Enabling regeneration by resetting stem cell divisions

    Slide 9: Our solution in Duchenne: Enabling regeneration by resetting stem cell divisions

    9 Our solution in Duchenne: Enabling regeneration by resetting stem cell divisions Duchenne Satellos Solution Satellos Drug Res ett ing Persistent damage signal triggers divisions in the ‘niche’ ste m cel l divisions in the ‘niche’ Oversupply of Not enough muscle Sufficient muscle Sufficient muscle

  10. Slide 10: About Duchenne: Deadly genetic disease desperately needing new treatments

    Slide 10: About Duchenne: Deadly genetic disease desperately needing new treatments

    10 About Duchenne: Deadly genetic disease desperately needing new treatments Duchenne Patient Journey Current Treatment Approaches Gene correction ▪ Rare genetic disease ▪ ~1 in 3,500 male births ▪ Dystrophin gene mutated Muscle Heart inflammation function Treat existing muscle tissue Muscle Energy/

  11. Slide 11: Proof of Concept: Satellos treatment improves outcomes in Duchenne model

    Slide 11: Proof of Concept: Satellos treatment improves outcomes in Duchenne model

    11 Proof of Concept (POC): Satellos treatment improves outcomes in Duchenne model Mdx Drug Enhanced Muscle Quality Mouse Que.: Can treatment ➢ Bigger muscle reset divisions? Resetting divisions ➢ Less fibrosis (green) ➢ Larger fibers (black) Untreated Diaphragm Treated Enhanced Muscle Performance An

  12. Slide 12: Mechanism of Action: How Satellos drug treatment resets stem cell divisions

    Slide 12: Mechanism of Action: How Satellos drug treatment resets stem cell divisions

    12 Mechanism of Action: How Satellos drug treatment resets stem cell divisions Treatment Approach Resetting divisions: ▪ Satellos discovered EGFR signalling capable of Satellos enforcing muscle stem cell divisions* Drug ▪ EGFR signalling in the ‘niche’ has potential to Inhibit reset divisions in Duc

  13. Slide 13: Drug development: Satellos infrastructure is producing significant results

    Slide 13: Drug development: Satellos infrastructure is producing significant results

    13 Drug development: Satellos infrastructure is producing significant results Drug Discovery Preclinical Biology ✓ Crystal structure of Target-X solved ✓ Demonstration of therapeutic benefit ✓ Co-crystals being developed in 2 Duchenne models ✓ Binding and activity assays ✓ Confirmation of mechanism

  14. Slide 14: Timeline: 12-Month plan for value inflection

    Slide 14: Timeline: 12-Month plan for value inflection

    14 Timeline 12-Month plan for value inflection 2021 2022 Q4 Q1 Q2 Q3 Output: Multiple candidates suitable for Proof Design / advance drug candidates and file IP of Concept (POC) testing and optimization Test / optimize lead drug candidates Pre-IND Lead Utility: Precedent in Duchenne for biomarkers t

  15. Slide 15: Significant value potential

    Slide 15: Significant value potential

    15 Significant value potential Attractive market capitalizations for peer companies Phase 3 / Commercial 36 – 60 months US$2.9BN US$7.7BN US$800M Phase 1 - 2 Trials 18 – 36 months US$250M US$1.0BN US$800M US$1.2BN Pre-IND/IND 12 – 18 months US$40M Development Stages Timeline Goals PEERS SATELLOS *Mk

  16. Slide 16: Satellos plan and goals for pipeline building

    Slide 16: Satellos plan and goals for pipeline building

    16 Satellos plan and goals for pipeline building Q4/21 Q1/22 Q2/22 Q3/22 Q4/22 Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Duchenne Drug Development Program Objectives by Q2/24 Follow-on Disease Indication (same drug) ✓ Pre-IND studies completed, and Objectives by Q2/24 IND application approved 2nd Program

  17. Slide 17: Leadership

    Slide 17: Leadership

    17 Leadership Frank Gleeson, MBA Michael Rudnicki, PhD, OC, FRS Sridhar Narayan, PhD, MBA Geoffrey Mackay Adam Mostafa William Jarosz, JD Co-founder and CEO Co-founder and CSO VP - Drug Discovery Chair — Board of Directors Chair – Audit Committee CEO, AmpB Technologies Inc. ▪ Past executive, VC and

  18. Slide 18: Corporate: Structure/Background

    Slide 18: Corporate: Structure/Background

    18 Corporate: Novel muscle regeneration Satellos Aug. 13, 2021 iCo Assets with clinical Structure/Background stem cell platform Bioscience Inc. Therapeutics Inc. trial data TSXV:MSCL Satellos Bioscience ▪ iCo-Satellos combination/RTO Inc. (TSXV: MSCL) announced March 22, 2021 100% owned 100% owned ▪

  19. Slide 19: Oral-Trans is AmpB Tech's patented formulation system

    Slide 19: Oral-Trans is AmpB Tech's patented formulation system

    19 Oral-Trans™ is AmpB Tech’s patented formulation system for solubilizing lipophilic compounds Oral Amp B Oral CBD Description: Description: • Orally formulated amphotericin B • Orally formulated CBD Advantage: Advantage: • Tolerability, toxicity • Simpler, more consistent admin. Target Application

  20. Slide 20: Cap Table and Key Professional Providers

    Slide 20: Cap Table and Key Professional Providers

    20 SATELLOS (TSXV: MSCL Cap Table and Key Professional Providers CAPITAL TABLE KEY PROVIDERS ▪ Legal: Borden Ladner Gervais, LLP ▪ David Henry, LLB, Partner Common Shares 32,995,548 ▪ Accounting: PricewaterhouseCoopers ▪ Craig McMillan, CPA, CA, Partner Warrants 2,162,762 ▪ IP Counsel (US): Cooley L

  21. Slide 21: Summary

    Slide 21: Summary

    21 ❑ Huge value potential in area of great medical need ❑ Initial focus on rare, lethal disease ‒ Duchenne ❑ Primary milestone in 2022 is a novel drug candidate Summary ❑ Disruptive science and work leading expertise ❑ Strong founders and leadership with clear plan Satellos Bioscience Inc. 65 Front

Source: Internet Archive copy of satellos.com

More decks from Satellos Bioscience Inc

All 17 Satellos Bioscience decks